Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.
Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.
Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.
Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.
Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.
For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.
Exelixis reported first-quarter 2021 financial results with total revenues of $270.2 million, up from $226.9 million year-over-year. Net product revenues reached $227.2 million, fueled by the FDA approval of CABOMETYX in combination with OPDIVO for advanced renal cell carcinoma. Despite revenue growth, GAAP net income dropped to $1.6 million from $48.6 million, reflecting increased R&D and administrative expenses. Exelixis maintains its 2021 revenue guidance of $1.15 to $1.25 billion.
Exelixis, Inc. (Nasdaq: EXEL) has entered into an agreement to acquire GamaMabs Pharma's AMHR2 antibody technology, paying $5 million upfront and additional milestone payments upon closing. This acquisition allows Exelixis to take control of GamaMabs' murlentamab, which demonstrated initial safety in clinical trials despite a halt in its development due to modest efficacy. Exelixis plans to apply its ADC capabilities to the AMHR2 technology aiming to expedite the development of novel cancer therapies, enhancing its biotherapeutics portfolio and addressing unmet patient needs.
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D. will participate in three virtual investor conferences in May 2021. These include the 7th Annual Truist Securities Life Sciences Summit on May 4 at 3:30pm EDT, the BofA Securities 2021 Health Care Conference on May 11 at 2:00pm EDT, and the RBC Capital Markets 2021 Global Healthcare Conference on May 19 at 3:05pm EDT. Webcasts can be accessed via the company's website, and replays will be available for 14 days.
Exelixis focuses on developing new medicines for challenging cancers, with four commercial products available.
Exelixis, Inc. (Nasdaq: EXEL) will announce its Q1 2021 financial results on May 6, 2021, after market close, followed by a conference call at 5:00 PM EDT. Investors can access the call via the company's website or by phone. Exelixis is an oncology-focused biotechnology firm known for products like CABOMETYX and COMETRIQ, dedicated to advancing cancer treatment through innovative therapies. The company is a member of the S&P MidCap 400 index and was recently recognized on Fortune's 100 Fastest-Growing Companies list, ranking 17th overall.
Exelixis, Inc. (Nasdaq: EXEL) has received FDA acceptance for its Investigational New Drug Application for XB002, a next-generation antibody-drug conjugate targeting tissue factor. This development marks a significant step toward clinical trials for patients with advanced solid tumors. Preclinical studies have shown that XB002 could offer improved safety and efficacy compared to earlier therapies, with evidence of tumor growth inhibition and complete regression in some models. The company aims to initiate a Phase 1 trial in the second quarter of 2021.
Exelixis, Inc. (Nasdaq: EXEL) announced that its partner Ipsen has received approval from the European Commission for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval covers all 27 EU member states, plus Norway, Iceland, and Liechtenstein. The decision is based on the CheckMate -9ER trial, which demonstrated significant improvements in progression-free survival, objective response rate, and overall survival when compared with sunitinib. CABOMETYX is also approved as a standalone treatment for advanced RCC.
Exelixis, Inc. (Nasdaq: EXEL) announced that the COSMIC-313 trial, evaluating cabozantinib (CABOMETYX), nivolumab (OPDIVO), and ipilimumab (YERVOY) for untreated advanced renal cell carcinoma, has completed enrollment. The trial enrolled about 840 patients at 180 sites worldwide. Primary endpoints include progression-free survival, with additional endpoints focusing on overall survival. This marks a significant advancement in understanding the potential benefits of the triplet therapy in kidney cancer treatment.
Exelixis announced a collaboration with Merck KGaA and Pfizer for the STELLAR-001 clinical trial, evaluating XL092, a next-generation tyrosine kinase inhibitor (TKI), in combination with avelumab, an anti-PD-L1 immune checkpoint inhibitor, for treating advanced urothelial carcinoma. The trial aims to assess safety and tolerability while potentially adding three expansion cohorts. XL092 targets various kinases implicated in cancer progression, and early preclinical results indicated enhanced efficacy when combined with immunotherapy. This partnership aims to improve outcomes for patients with challenging cancers.
Exelixis (Nasdaq: EXEL) has formed an exclusive license agreement with WuXi Biologics to advance its oncology biologics pipeline. The deal includes an upfront payment for a panel of monoclonal antibodies aimed at tumor-targeting biologics. This collaboration follows the FDA's fourth approval of Exelixis' flagship product, CABOMETYX, earlier this year. Exelixis aims to leverage WuXi Bio's technology and expertise to enhance its biotherapeutics portfolio, thus improving cancer treatment options.
Exelixis (NASDAQ: EXEL) announced that its partner Ipsen has obtained a positive opinion from the CHMP for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced kidney cancer. Following the FDA approval in the U.S., this recommendation marks progress towards making this treatment available in Europe. CABOMETYX is already approved in the EU for various conditions, and its combination with OPDIVO has shown promising results, significantly improving patient outcomes in clinical trials.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is Exelixis Inc. known for?
What are the main products of Exelixis?
When was Cometriq first approved?
Who are the key partners of Exelixis?
What type of cancer is Cometriq used to treat?
What is Cabometyx used for?
Where can I find job opportunities at Exelixis?
How has the financial performance of Exelixis been?
What kind of research does Exelixis focus on?
What is the ticker symbol for Exelixis Inc.?
